Fairmount Funds Management LLC insider trades: Crescent Biopharma (CBIO) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Fairmount Funds Management LLC reports to the SEC
and 7 more companies
Open-market buys and sales
26 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | CBIO | ↑ Buy | 853,450 | $14.50 | $12.4M | By Fairmount Healthcare Fund II L.P. | Jul 20, 2026 (4d) |
| Jul 1, 2026 | ORKA | ↓ Sell | 3,553,410 | $84.43 | $300.0M | By Fairmount Healthcare Fund II L.P. | Jul 1, 2026 (0d) |
| Jun 23, 2026 | SYRE | ↓ Sell | 4,684,781 | $85.31 | $399.7M | By Fairmount Healthcare Fund II L.P. | Jun 23, 2026 (0d) |
| May 11, 2026 | VRDN | ↑ Buy | 1,176,470 | $17.00 | $20.0M | By Fairmount Healthcare Fund II L.P. | May 13, 2026 (2d) |
| Mar 31, 2026 | ZBIO | ↑ Buy | 150,000 | $20.00 | $3.0M | By Fairmount Healthcare Fund II L.P. | Apr 1, 2026 (1d) |
| Mar 31, 2026 | COGT | ↓ Sell | 7,000,000 | $34.66 | $242.6M | Fairmount Healthcare Fund II LP | Mar 31, 2026 (0d) |
| Jan 22, 2026 | APGE | ↓ Sell | 1,750,000 | $76.30 | $133.5M | By Fairmount Healthcare Fund II LP | Jan 22, 2026 (0d) |
| Jan 22, 2026 | COGT | ↓ Sell | 3,500,000 | $36.40 | $127.4M | Fairmount Healthcare Fund II LP | Jan 22, 2026 (0d) |
| Dec 4, 2025 | CBIO | ↑ Buy | 1,360,000 | $13.41 | $18.2M | By Fairmount Healthcare Fund II L.P. | Dec 8, 2025 (4d) |
| Oct 23, 2025 | VRDN | ↑ Buy | 454,545 | $22.00 | $10.0M | Fairmount Healthcare Fund II LP | Oct 27, 2025 (4d) |
| Oct 7, 2025 | ZBIO | ↑ Buy | 316,219 | $19.00 | $6.0M | By Fairmount Healthcare Fund II L.P. | Oct 9, 2025 (2d) |
| Jul 10, 2025 | COGT | ↑ Buy | 2,777,777 | $9.00 | $25.0M | Fairmount Healthcare Fund II LP | Jul 14, 2025 (4d) |
| Sep 16, 2024 | ZBIO | ↑ Buy | 300,000 | $17.00 | $5.1M | By Fairmount Healthcare Fund II LP | Sep 16, 2024 (0d) |
| Sep 13, 2024 | VRDN | ↑ Buy | 1,600,000 | $18.75 | $30.0M | Fairmount Healthcare Fund II LP | Sep 17, 2024 (4d) |
| Jan 22, 2024 | VRDN | ↑ Buy | 476,190 | $21.00 | $10.0M | Fairmount Healthcare Fund II LP | Jan 24, 2024 (2d) |
| Sep 29, 2023 | DNTH | ↑ Buy | 24,670 | $13.63 | $336K | Indirect | Oct 3, 2023 (4d) |
| Sep 26, 2023 | DNTH | ↑ Buy | 30,000 | $13.15 | $395K | Indirect | Sep 28, 2023 (2d) |
| Sep 19, 2023 | DNTH | ↑ Buy | 30,000 | $13.20 | $396K | Indirect | Sep 21, 2023 (2d) |
| Sep 13, 2023 | DNTH | ↑ Buy | 24,254 | $11.20 | $272K | Indirect | Sep 13, 2023 (0d) |
| Jul 13, 2023 | APGE | ↑ Buy | 1,992,734 | $17.00 | $33.9M | By Fairmount Healthcare Fund II LP | Jul 17, 2023 (4d) |
| Jul 13, 2023 | APGE | ↑ Buy | 892,529 | $17.00 | $15.2M | By Fairmount Healthcare Co-Invest II LP | Jul 17, 2023 (4d) |
| Jul 13, 2023 | APGE | ↑ Buy | 55,913 | $17.00 | $951K | By Fairmount Healthcare Fund LP | Jul 17, 2023 (4d) |
| Jun 9, 2023 | COGT | ↑ Buy | 800,000 | $12.00 | $9.6M | Fairmount Healthcare Fund II LP | Jun 13, 2023 (4d) |
| Aug 17, 2022 | VRDN | ↑ Buy | 425,531 | $23.50 | $10.0M | Fairmount Healthcare Fund II LP | Aug 19, 2022 (2d) |
| Jun 16, 2022 | COGT | ↑ Buy | 1,200,000 | $8.25 | $9.9M | Fairmount Healthcare Fund II LP | Jun 21, 2022 (5d) |
| Sep 21, 2021 | VRDN | ↑ Buy | 909,000 | $11.00 | $10.0M | Fairmount Healthcare Fund II LP | Sep 23, 2021 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CBIO insiders
Open-market trades in the last 12 months
About Fairmount Funds Management LLC's insider trades
Fairmount Funds Management LLC is a director at Crescent Biopharma (CBIO). Since Sep 21, 2021, it has reported 21 open-market purchases worth $230.6M and 5 sales worth $1.20B on SEC Form 4. In the last 12 months: 4 buys ($53.6M) and 5 sales ($1.20B).
Its filings also include grants and awards (24 filings), other transactions (13 filings), option exercises (6 filings), conversions (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CBIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.